Calithera Biosciences Inc Financials
This page shows Calithera Biosciences Inc (CALA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Calithera's recent filings show a cost-cutting-driven reset inside a cash-consuming development-stage model still reliant on new financing.
From FY2021 to FY2022, net loss narrowed from-$115.1M to-$39.7M as the company shrank its operating footprint. R&D spending nearly halved, yet year-end cash of$25.5M was still below FY2022 operating cash outflow of-$43.6M , so the improvement came from retrenchment rather than a self-funding business.
FY2022 ended with a current ratio of 3.6x and only
Cash losses and accounting losses were closely aligned, with FY2022 operating cash flow of
Financial Health Signals
Calithera Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Calithera Biosciences Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Calithera Biosciences Inc reported a net loss of $39.6M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Calithera Biosciences Inc's EBITDA was -$41.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 63.7% from the prior year.
Calithera Biosciences Inc reported -$39.6M in net income in fiscal year 2022. This represents an increase of 65.5% from the prior year.
Calithera Biosciences Inc earned -$7.94 per diluted share (EPS) in fiscal year 2022. This represents an increase of 74.5% from the prior year.
Not reported for fiscal year 2022.
Cash & Balance Sheet
Calithera Biosciences Inc recorded an outflow of $43.7M in free cash flow in fiscal year 2022, representing a cash shortfall after capex. This represents an increase of 34.2% from the prior year.
Calithera Biosciences Inc held $25.5M in cash as of fiscal year 2022; long-term debt is not reported for that period.
Not reported for fiscal year 2022.
Margins & Returns
Calithera Biosciences Inc's ROE was -194.4% in fiscal year 2022, measuring profit generated per dollar of shareholder equity. This is up 1178.6 percentage points from the prior year.
Not reported for fiscal year 2022.
Not reported for fiscal year 2022.
Not reported for fiscal year 2022.
Capital Allocation
Calithera Biosciences Inc invested $28.5M in research and development in fiscal year 2022. This represents a decrease of 46.6% from the prior year.
Calithera Biosciences Inc invested $133K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 9.5% from the prior year.
Not reported for fiscal year 2022.
CALA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $9.8M | N/A | N/A | $22.3M-14.3% | $26.0M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $28.5M-46.6% | $53.5M-24.7% | $71.0M-6.9% | $76.3M+15.3% | $66.2M+53.5% | $43.1M+55.4% | $27.7M+16.8% | $23.7M+45.1% | $16.4M+65.3% | $9.9M+51.0% | $6.6M |
| SG&A Expenses | $13.5M-35.1% | $20.9M+2.4% | $20.4M+22.7% | $16.6M+24.5% | $13.3M+6.5% | $12.5M+18.4% | $10.6M+16.7% | $9.1M+69.4% | $5.4M+116.1% | $2.5M+74.9% | $1.4M |
| Operating Income | -$42.1M+63.6% | -$115.4M-26.3% | -$91.4M+1.6% | -$92.9M-62.2% | -$57.3M-93.0% | -$29.7M+22.6% | -$38.3M-16.8% | -$32.8M-51.1% | -$21.7M-75.5% | -$12.4M-55.2% | -$8.0M |
| Interest Expense | N/A | N/A | N/A | N/A | $2.7M+42.6% | $1.9M+463.6% | $330K+88.6% | $175K+1844.4% | $9K+800.0% | $1K | N/A |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$39.6M+65.5% | -$115.1M-27.7% | -$90.1M-0.3% | -$89.9M-64.5% | -$54.6M-96.3% | -$27.8M+26.8% | -$38.0M-16.4% | -$32.6M-50.4% | -$21.7M-75.4% | -$12.4M-55.2% | -$8.0M |
| EPS (Diluted) | -$7.94+74.5% | -$31.16 | -$26.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CALA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.7M-55.7% | $64.8M-48.4% | $125.6M-25.6% | $168.8M+18.2% | $142.7M-25.8% | $192.5M+251.2% | $54.8M-27.7% | $75.8M-27.7% | $104.8M+200.7% | $34.8M | N/A |
| Current Assets | $26.6M-56.7% | $61.5M-48.2% | $118.7M-25.7% | $159.8M+13.9% | $140.3M-16.4% | $167.7M+213.0% | $53.6M-26.1% | $72.5M-30.2% | $103.9M+204.0% | $34.2M | N/A |
| Cash & Equivalents | $25.5M-57.3% | $59.5M-44.4% | $107.1M+77.3% | $60.4M+18.4% | $51.1M+5.3% | $48.5M+357.3% | $10.6M+73.6% | $6.1M-94.0% | $102.0M+201.5% | $33.8M+1433.8% | $2.2M |
| Accounts Receivable | N/A | N/A | $1.5M+219.7% | $482K-75.9% | $2.0M+74.9% | $1.1M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.3M-85.3% | $56.4M+142.8% | $23.2M-11.9% | $26.3M+64.5% | $16.0M-62.0% | $42.1M+761.9% | $4.9M+23.4% | $4.0M-10.0% | $4.4M-92.1% | $55.7M | N/A |
| Current Liabilities | $7.4M-47.2% | $14.0M-23.9% | $18.4M-6.2% | $19.6M+31.9% | $14.9M-61.9% | $39.0M+776.4% | $4.5M+16.2% | $3.8M-7.0% | $4.1M+206.6% | $1.3M | N/A |
| Total Equity | $20.4M+143.3% | $8.4M-91.8% | $102.4M-28.1% | $142.4M+12.4% | $126.7M-15.7% | $150.3M+201.2% | $49.9M-30.5% | $71.8M-28.5% | $100.4M+582.2% | -$20.8M-142.8% | -$8.6M |
| Retained Earnings | -$512.6M-4.3% | -$491.3M-30.6% | -$376.2M-31.5% | -$286.1M-45.8% | -$196.2M-30.5% | -$150.3M-22.7% | -$122.5M-45.0% | -$84.5M-63.0% | -$51.9M-72.0% | -$30.1M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CALA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$43.6M+34.2% | -$66.3M+21.4% | -$84.3M-7.1% | -$78.7M-21.4% | -$64.8M-571.5% | $13.8M+144.3% | -$31.0M-3.6% | -$29.9M-55.6% | -$19.2M-62.5% | -$11.8M-69.3% | -$7.0M |
| Capital Expenditures | $133K-9.5% | $147K+141.0% | $61K+771.4% | $7K-96.7% | $214K-82.6% | $1.2M+206.5% | $401K-9.1% | $441K-20.7% | $556K+239.0% | $164K+234.7% | $49K |
| Free Cash Flow | -$43.7M+34.2% | -$66.4M+21.2% | -$84.4M-7.1% | -$78.8M-21.1% | -$65.1M-619.5% | $12.5M+139.8% | -$31.4M-3.5% | -$30.4M-53.5% | -$19.8M-64.9% | -$12.0M-70.5% | -$7.0M |
| Investing Cash Flow | -$133K-101.7% | $7.9M-91.2% | $89.0M+924.9% | -$10.8M-120.4% | $52.8M+153.6% | -$98.4M-515.2% | $23.7M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $9.7M-9.5% | $10.7M-74.6% | $42.1M-57.5% | $98.9M+576.2% | $14.6M-88.1% | $122.9M+940.5% | $11.8M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CALA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -1183.9% | N/A | N/A | -257.4% | -114.4% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -1180.4% | N/A | N/A | -245.5% | -107.2% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -194.4%+1178.6pp | -1373.0%-1285.0pp | -88.0%-25.0pp | -63.1%-20.0pp | -43.1%-24.6pp | -18.5%+57.6pp | -76.1%-30.7pp | -45.5%-23.8pp | -21.6% | N/A | N/A |
| Return on Assets | -138.3%+39.5pp | -177.7%-106.0pp | -71.8%-18.5pp | -53.2%-15.0pp | -38.3%-23.8pp | -14.5%+54.9pp | -69.4%-26.3pp | -43.1%-22.4pp | -20.7%+14.8pp | -35.5% | N/A |
| Current Ratio | 3.60-0.8x | 4.39-2.1x | 6.45-1.7x | 8.14-1.3x | 9.42+5.1x | 4.30-7.7x | 12.03-6.9x | 18.91-6.3x | 25.20-0.2x | 25.42 | N/A |
| Debt-to-Equity | 0.41-6.3x | 6.73+6.5x | 0.230.0x | 0.18+0.1x | 0.13-0.2x | 0.28+0.2x | 0.100.0x | 0.060.0x | 0.04 | N/A | N/A |
| FCF Margin | N/A | -681.5% | N/A | N/A | -292.3% | 48.3% | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Calithera Biosciences Inc Ranks
Frequently Asked Questions
Is Calithera Biosciences Inc profitable?
No, Calithera Biosciences Inc (CALA) reported a net income of -$39.6M in fiscal year 2022.
What is Calithera Biosciences Inc's EBITDA?
Calithera Biosciences Inc (CALA) had EBITDA of -$41.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is Calithera Biosciences Inc's return on equity (ROE)?
Calithera Biosciences Inc (CALA) has a return on equity of -194.4% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.
What is Calithera Biosciences Inc's free cash flow?
Calithera Biosciences Inc (CALA) recorded an outflow of $43.7M in free cash flow during fiscal year 2022. This represents a 34.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Calithera Biosciences Inc's operating cash flow?
Calithera Biosciences Inc (CALA) recorded an outflow of $43.6M in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are Calithera Biosciences Inc's total assets?
Calithera Biosciences Inc (CALA) had $28.7M in total assets as of fiscal year 2022, including both current and long-term assets.
What are Calithera Biosciences Inc's capital expenditures?
Calithera Biosciences Inc (CALA) invested $133K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Calithera Biosciences Inc spend on research and development?
Calithera Biosciences Inc (CALA) invested $28.5M in research and development during fiscal year 2022.
What is Calithera Biosciences Inc's current ratio?
Calithera Biosciences Inc (CALA) had a current ratio of 3.60 as of fiscal year 2022, which is generally considered healthy.
What is Calithera Biosciences Inc's debt-to-equity ratio?
Calithera Biosciences Inc (CALA) had a debt-to-equity ratio of 0.41 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Calithera Biosciences Inc's return on assets (ROA)?
Calithera Biosciences Inc (CALA) had a return on assets of -138.3% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Calithera Biosciences Inc's cash runway?
Based on fiscal year 2022 data, Calithera Biosciences Inc (CALA) had $25.5M in cash against an annual operating cash burn of $43.6M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Calithera Biosciences Inc's Piotroski F-Score?
Calithera Biosciences Inc (CALA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Calithera Biosciences Inc's earnings high quality?
Calithera Biosciences Inc (CALA) reported a net loss of $39.6M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.